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Summary
Objective: to estimate the prevalence of osteoporosis in pa-
tients being treated with thyroid hormone.
Method: cross-sectional retrospective study of primary care
patients.
Experimental Group: patients diagnosed with subclinical hy-
pothyroidism receiving thyroid hormone replacement therapy. 
Control Group: patients not receiving replacement therapy.
Once the sample was selected its members were summoned
to complete a clinical questionnaire and undergo a bone den-
sity scan with a validated measuring device.
The description of qualitative data was done in absolute fre-
quencies and percentages and that of the quantitative data
as mean standard deviation, median.
In the comparison of qualitative data between groups we used
the Chi-square test and contingency tables by rearranging the
percentages of several variables.
Results: 182 patients were studied (112 experimental and 70
control), diagnosed  with subclinical hypothyroidism. The ave-
rage age at diagnosis was 42.5 and 41.2 years, respectively.
32.7% and 33.2% were smokers. In the experimental group
the coexistence of two or more cardiovascular risk factors
was detected in 5.7% of the patients. Mean TSH was 6.67 mU/L,
mean freeT4 1,04 ng/dl. 
67% of the patients studied had some level of bone loss: 87%
osteopenia and 14% osteoporosis. 56% of those suffering from
bone less were women. With regard to the size of the thyroid
hormone treatment, only 12% received 150 µg/day or more.
61% had received treatment for between 5 and 10 years and
19.5% for more than 10 years. 
Conclusions: there is a high prevalence of bone loss in pa-
tients with subclinical hypothyroidism treated with exogenous
thyroxin. 
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Introduction
Osteoporosis (OP) is a skeletal disease characterized by redu-
ced bone strength which predisposes to an increased risk of frac-
ture. Bone strength is primarily a function of  bone density and qua-
lity. Bone density is expressed as grams of mineral per area or
volume and in any given individual is determined by  peak bone
mass and the amount of bone loss. Bone quality refers to macro-
and micro-architecture, bone turnover, size, accumulated dama-
ge (e.g. microfractures) and mineralization (1-3).
The definition of osteoporosis (OP) by the World Health Organi-
zation (WHO) is densitometric and non-clinical and is based on
the measurement of bone mass with the DEXA method in the spi-
ne or hip. It establishes four categories: normal, osteopenia, osteo-
porosis and established osteoporosis. The presence of patholo-
gical low bone mass,  osteopenia or osteoporosis, is the best in-
dicator of fracture risk for the region where the bone mass is mea-
sured, hence its interest, since bone loss is asymptomatic until it
produces its natural consequence: the osteoporotic fracture
(OF) (4-6).
OP is a health issue with important implications for individuals, fa-
milies and the community. Untreated OP results in unnecessary
pain, restriction of function (disability), decreased quality of life,
altered body image with low self-esteem, increased mortality and
serious economic consequences (7, 8).
In Spain it is estimated that osteoporosis causes 500,000 fractures
a year and is responsible for 80,000 hospital stays. The annual
incidence of hip fracture in patients over 50 ranges between 2 and
3 per 1000, with a male/female ratio of 2 or 3:5. These are the inju-
ries with the most serious social and health consequence with acu-
te phase mortality in hospitalized patients ranging from 5% to 8%,
a figure that rises to between 20% and 30% in the first year. It is
estimated that among survivors only a third return to their inde-
pendent status prior to the fracture,  while one third will require
home care, and the remaining third will depend on a chronic care
center (9-11).
Moreover, one in five women over the age of 50 has a spinal frac-
ture and although some are asymptomatic and related mortality
is low, some produce chronic pain, height loss, respiratory pro-
blems, constipation and abdominal pain, which limit the activity
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and quality of life  of patients who suffer these symptoms (12-14).
The high prevalence and easy deployment of the available the-
rapeutic arsenal and the characteristics of primary care (PC) re-
lating to patient accessibility, early diagnosis and treatment
compliance make PC the optimum stage of care for the preven-
tion, diagnosis and care of the osteoporotic patient, a view con-
firmed by organizations as prestigious as the  National Osteoporosis
Foundation (NOF) (14).  There exist criteria for referral for cases
that require the patient to be referred to other levels of care. The-
se criteria will be addressed in this paper.
Subclinical hypothyroidism is defined by experts as a condition of
mild thyroid failure characterized by normal levels of  T3 and T4 with
moderately elevated serum TSH between 5 and 10 mU/L (15, 16).
Increased access to serological tests for TSH have resulted in an
increase in the number of patients with abnormal thyroid function,
but not necessarily symptomatic. This has led to a series of disputes
among experts regarding the management and diagnosis of the-
se patients (17, 18) . Subclinical hypothyroidism is a common con-
dition, especially in middle aged and older adults. Its reported pre-
valence is between 3.9 and 6.5% in foreign studies (19, 20)  and
5.6%  in Chile (21).  It is twice as frequent among women as men
and 3 times more frequent among white people (20). Various stu-
dies have shown that 30% of patients with subclinical hypothy-
roidism developed hypothyroidism within 10 years and only 4%
of patients with subclinical hypothyroidism normalized their TSH
values. Factors influencing the progress of hypothyroidism are le-
vels of TSH and the presence of antimicrosomal antibodies (21).
There are no studies showing a reduction in mortality in patients
with subclinical hypothyroidism treated with thyroid hormone. With
regard to the general symptoms of hypothyroidism, cohort studies
have shown no significant difference in the presence of constipation,
fatigue or lack of energy in patients with subclinical hypothyroidism
and euthyroid patients (22).
Some authors have suggested that treatment with levothyroxine
may cause long-term osteoporosis, but there is no evidence to sup-
port this theory, and studies have shown no difference in bone den-
sity or fracture risk in those patients treated (23).  A century ago
Von Recklinghausen described the bone condition thyrotoxicosis.
Hyperthyroidism is one of the endocrine diseases classically as-
sociated with osteoporosis. The effect of hyperthyroidism on bone
remodeling and metabolism has been thoroughly described. Mundy
and his collaborators demonstrated in 1975 that  T4 and T3 can
directly stimulate bone resorption in vitro. In addition, the normal
bone remodeling cycle is reduced from 200 to 113 days, mainly
at the expense of the formation period with a failure to replenish
the bone. Both the formation markers of bone resorption may be
elevated (24, 25).
Patients with endogenous hyperthyroidism have reduced BMD com-
pared with euthyroid controls. It has been shown that the treat-
ment produced a significant increase in trabecular BMD (26). 
Exogenous administration of suppressive doses of thyroxin may
have a negative effect on BMD.  Diamond and  his collaborators
found a decrease in femoral neck BMD in pre-and post-menopausal
women with thyroid carcinoma treated with suppressive doses of
thyroxin; the reduction in lumbar spine BMD was significant only
in post-menopausal women. Other controlled studies show no chan-
ges in BMD with suppressive therapy (27). 
For all these reasons we decided to estimate the prevalence of
osteoporosis in patients treated with thyroid hormone, conside-
ring such factors as the dose of thyroxin and thyrotropin levels,
as well as the treatment time.
Method 
This is a retrospective cross-sectional study of primary care pa-
tients.
Patients: a sample of 112 patients was drawn up, collected  ran-
domly and consecutively with an assumed confidence rate of  95%.
The prerequisites for belonging to the sample were to be over 14
and  have a  TSH level of  4.5 mU/L and free T4 levels in the nor-
mal range (0.8-1.2 ng/dl) and to be being treated with thyroid hor-
mone replacement for the experimental group and not to be re-
ceiving such treatment for the control group.
Experimental group: patients diagnosed with subclinical hy-
pothyroidism receiving thyroid hormone replacement therapy in
the period June 2005 to January 2006. Control Group: patients
with subclinical hypothyroidism not receiving replacement therapy.
In all cases the following variables were analyzed: anthropome-
tric, family and personal history, CBC and biochemical analysis,
thyroid hormones, being diagnosed with subclinical hypothyroidism
and receiving thyroid hormone replacement therapy.  Once the
sample was selected its members were summoned to complete
a clinical questionnaire and undergo a bone density scan with a
validated measuring device.
The description of qualitative data was done in absolute frequencies
and percentages and  the quantitative data as mean standard de-
viation, median, minimum and maximum.
In the comparison of qualitative data between groups we used
the Chi-square test and contingency tables by rearranging the
percentages of several variables (TSH, total cholesterol, HDL-
C, LDL-c).
Results
182 patients were studied (112  experimental and 70 control), all
diagnosed with subclinical hypothyroidism in the age range
between 14 and 65 inclusive (Table 1).
As has already been mentioned, if it is estimated that there were
1040 consultations in this period it suggests that there would be
an incidence of about 5% of new cases over a period of 6 months.
Patients presented with the following symptoms, which eventually
led to diagnosis:
 Weight change (3.8%)
 Gynecological reasons (11.5%)
 Symptoms of depression (5.8%)
 Alopecia (5.8%)
 Musculoskeletal pains (11.5%)
 Non-specific fatigue-dizziness (30.8%)
Among the subjects studied 32.7% of the experimental group and
33.2% of the control group were smokers.
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Table 1 - General data.
Variables Experimental Control
Age 42.5 41.2
Sex 88.5% women 81.5% women
Smokers 32.7% 33.2%
No cardiovascular risk factors 81.2% 80.3%
Diabetes 2.8% 2.5%
Hypertension 5.7% 5.1%
Variables experimental control
Lipid disorders 1.9% 1.5%
Body Mass Index 25.67 24.76
Systolic arterial pressure 119.75 115
Dystolic arterial pressure 71.86 70.5
Glycemia 87.71 90
Total cholesterol 193.92 195
TSH 6.67 5.95
T4 1.09 0.98
CVR score <5% <5%
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The association obtained between sex and TSH is close to being
statistically significant in both groups with p= 0.08. For this rea-
son we may assume that sex is a variable which may be depen-
dent on TSH. In fact, when we look at the data obtained we can
see that TSH is not  distributed equally between the sexes but rather
is predominant among women, regardless of the TSH range with
which we are concerned. It remains the case, however, that 88.5%
of the participants in the study were women.
With regard to the association between TSH and age a result clo-
se to statistical significance was obtained; p = 0,005 (p < 0,05).
We may thus assume that TSH is a variable dependent on age.
It must be remembered, however, that the subjects of this study
were relatively young, with an average age of 42.4 years.
No statistically significant associations were found between TSH
and the Body Mass Index (BMI), and the majority of patients had
a normal BMI (up to 25), independently of the TSH values found.
With regard to the association between TSH and cholesterol (esti-
mated for two ranges, one to 220 mg/dl and another >20 mg/dl)
a figure close to statistical significance  was found in both grou-
ps; p = 0.056.
It should be pointed out that a relationship close to statistical si-
gnificance, p = 0.08, was found between high TSH and a raised
level of LDL and triglycerides.
With regard to the association between TSH and fasting gluco-
se, a predominance of unaltered fasting glucoses (up to 110) was
found, regardless of the TSH range and there was no statistical-
ly significant  relationship found.
A statistically significant  relationship was found between TSH and
mean  free T4: p=0.04  (p>0.05), thus verifying feedback mecha-
nism that regulates thyroid physiology.
Regarding diastolic blood pressure levels; it was found to be less
than 90mmHg in most patient ranges with their being a statisti-
cally significant relationship between altered TSH and normal dia-
stolic blood pressure levels (p<0.05). A similar result was produ-
ced in the case of systolic blood pressure with the bulk of patients
having a lower level than 140 mmHg, compared with those with
higher values. 
With regard to bone parameters it can be seen that there is a clearly
significant difference  in the experimental group both in terms of
degree of bone mass loss, significantly related to sex (p>0.05),
and years of treatment for hypothyroidism  (p>0.039) and in terms
of osteopenia  and osteoporosis. Nevertheless there is no rela-
tionship  with the dose of thyroid hormone being taken nor with
levels of TSH or  T4 (Table 2).
A statistically significant relationship was observed between bone
mass grade and Z score which suggests that the latter is a good
variable to use for diagnosis (Table 3).
Discussion
Subclinical hypothyroidism is defined by experts as a condition of
mild thyroid failure characterized by normal levels of T3 and T4 with
moderately elevated serum TSH of between 5 and 10 mU/L (1-
4).
Analyzing the results we can see that the “symptoms” of this con-
dition include  weight changes, various gynecological issues (chan-
ges in the duration and amount of the cycle, infertility), depressi-
ve symptoms, alopecia, musculoskeletal pain and nonspecific fa-
tigue and dizziness. These are the reasons for which patients pre-
sent themselves and which lead to a request for TSH to be mea-
sured.
The prevalence of subclinical hypothyroidism in our 5%, is con-
sistent with other studies (5-11).
Although at an appropriate dose thyroxin is a very safe  medici-
ne, before treatment begins  a number of possible  side effects
must be considered including restoration of euthyroidism, the exa-
cerbation of ischemic heart disease  and the production of acu-
te adrenal insufficiency. Care must be taken to get the dose right,
since an excess can lead to decreased bone mineral density, the
onset of atrial arrhythmias and the precipitation of angina pecto-
ris. Although there have been no descriptions of such complica-
tions arising, patients with coronary artery disease should initial-
ly receive a lower dose of levothyroxine, usually 12.5 to 25 µg per
day,  with this does being  reassessed in 4 to 6 weeks depending
on  successive determinations of TSH and the clinical assessment.
This is not the case with elevated TSH and normal T4 as the  ad-
verse effects of thyroxin outweigh the benefits in patients with sub-
clinical hypothyroidism scheduled for urgent or semi-elective sur-
gery or invasive methods.  Such procedures should not be delayed
because there is no evidence of increased risk of complications
or mortality, even in  cases of established hypothyroidism(12-14).
The relationship between bone mass and thyroid functional sta-
tus is an issue of utmost importance and currently controversial.
Thyroid hormones are essential for growth and development du-
ring childhood and for the maintenance of bone in adulthood. In
children with hypothyroidism one sees stunted growth with
epiphyseal dysgenesis and delayed skeletal maturation while in
adults the phases of bone renewal are prolonged with  reduced
osteoblast activity and increased cortical bone thickness. Howe-
ver, the most pronounced effects of thyroid hormones on bone in
adults are seen in hyperthyroidism. Hyperthyroidism is a common
pathology, with a prevalence of 2% in women and 0.2% in men.
Despite treatment, in the long term, the mortality rate increases
in this latter population to 2.9% as a result of the aftermath of fe-
moral neck fractures (20). In a review of the impact of hyperthy-
roidism on bone, it was noted that 8% of patients had symptomatic
bone disease, all women, mostly postmenopausal, of whom 65%
had severe bone pain or evidence of fractures and up to 75% had
been thyrotoxic for  less than 1 year (28-32).
The pathogenic mechanism affecting the bone in hyperthyroidi-
sm is based on the increase both  in the number and turnover rate
of bone turnover units and  thus an increase in osteoclast and osteo-
blast activity, with remodeling cycle time reduced by 50% and in-
creased frequency of activation of units. These changes lead to
an uncoupling between resorption and formation, with the net re-
sult of loss of mineralized bone in varying amounts depending on
factors such as sex, menstrual function, thyroid disease severity
and  sum of other risk factors for osteoporosis (31-34).
At present there is little doubt about the deleterious effect of hy-
perthyroidism on bone, but controversy persists in two situations
we will discuss in more detail because of their frequency and cli-
nical implications: subclinical hyperthyroidism and chronic treat-
ment with thyroid hormones.
Technical improvements have allowed more and more sensitive
measurements of the levels of the hormone thyrotropin (TSH), whi-
ch are a reliable indicator of the tissue activity of the thyroid hor-
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Table 2 - Treatment data.
Variables Experimental Control
Dose 72% 100 µg or more 0
Years of treatment 61,1% 5-10 years 0
Table 3 - Bone metabolims data.
Variables Experimental Control
Bone mass loss 67% 35% p: 0.002
Osteopenia 86% 54% p: 0.001
Osteoporosis 14% 5% p: 0.001
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mone (TH), so that if  its  levels are suppressed,  even with  HT
still remain within normal limits, we can say that there exists  a de-
gree of tissue hyperthyroidism, a clinical condition known as sub-
clinical hyperthyroidism, with a prevalence of 1%, progressing to
frank hyperthyroidism in approximately 5% of cases each year.
Given that the loss of bone mass resulting from hyperthyroidism,
is only partially reversible, it seems logical that we should treat this
condition situation as soon as possible, if it is shown that it is al-
tering the bone metabolism. The controversy persists because  early
work showed that there was an increase of bone turnover in sub-
clinical hyperthyroidism, but a recent study, which examined the
correlations of TSH with bone mineral density during follow-up pe-
riods of 4 to 6 years, failed to demonstrate any difference
between the groups with suppressed, normal or high TSH (31-34).
However, in another study it has been confirmed that patients trea-
ted to maintain the euthyroid preserved bone density in the spi-
ne and hip, compared to untreated patients who suffered a 2% an-
nual decline (19). Despite the controversy, the most prevalent trend
today is to treat subclinical hyperthyroidism early, not only due to
its potential impact on the bone, but also because of the cardio-
vascular risks it brings with it, such as the increased incidence of
atrial fibrillation arrhythmias (24, 25).
Chronic treatment with thyroid hormones and  its  relationship to
osteoporosis, the objective of this study, is one of the areas in whi-
ch most work  has been done in recent years. Here we must fo-
cus on two clearly different  therapeutic objectives: suppressive
treatment with thyroid hormones (with the objective of suppres-
sing TSH levels, for example the treatment used after surgery and
radioiodine in differentiated thyroid carcinomas) and replacement
therapy (with the goal of normalizing  TSH levels, such as that used
in the primary autoimmune hypothyroidism). With suppressive the-
rapy the patient is maintained in a state of subclinical hyperthy-
roidism, showing in most studies an increased bone turnover. A
recent meta-analysis  which included 1,250 patients from 41 stu-
dies, stratifying patients according to sex, menopausal status, dose
of HT and anatomical site in which densitometry was carried out,
and excluding those who had previous hyperthyroidism, concluded
that suppressive treatment caused a significant loss of bone mass
in the lumbar spine and hip in postmenopausal women only, with
a more pronounced effect in the cortical bone. The loss was less
than 1 standard deviation on average: 7% in lumbar spine, 5% in
femoral neck, 9% in Ward’s triangle and 7% in the distal portion
of the radius (29). These results should be  regarded with caution
and confirmed with controlled studies to look at both bone den-
sity and the incidence of fractures.
In the case of HT replacement therapy no deleterious effect on
bone has been shown, so it is necessary to properly monitor TSH
levels during the long-term suppression of TSH  only in those ca-
ses where it is absolutely necessary (high risk follicular thyroid car-
cinomas) and decide on the balance between the  risks and be-
nefits of treatment of thyroid nodular disease with suppressive do-
ses of l-T (4,12,14). Exogenous administration of suppressive do-
ses of thyroxine may have a negative effect on BMD. Diamond
and colleagues found a decrease in femoral neck BMD in pre-and
postmenopausal women with thyroid carcinoma treated with sup-
pressive doses of thyroxin, reduction in lumbar spine BMD was
significant only in postmenopausal women. Exogenous admini-
stration of suppressive doses of thyroxin may have a negative ef-
fect on BMD. Diamond and his collaborators found a decrease in
femoral neck BMD in pre- and postmenopausal women with thy-
roid carcinoma treated with suppressive doses of thyroxin, the re-
duction in lumbar spine BMD was significant only in postmeno-
pausal women (34).
Other controlled studies show no changes in BMD with suppressive
therapy. Such factors as the dose of thyroxine and level of thy-
rotropin should be considered when it comes to analyzing these
studies with conflicting results, while also taking into account is-
sues related to the research design (1-3).
In our study we observed a high prevalence of bone loss in pa-
tients treated with thyroxin, which although not related to the dose
they are taking was related to the number of years for which they
had been taking it. This clearly leads to the  decision that we must
be cautious in starting treatment and although subclinical hy-
pothyroidism occurs in young people they should only be treated
when it is really necessary to do so.
Currently, no clinical practice guidelines recommend the use of
treatments for osteoporosis in patients initiating treatment with exo-
genous thyroxin, but considering the results of this present study
consideration should at least be given to  periodic BMD studies
to establish the earliest possible treatment.
In the light of all this there is a need for deeper study of subclini-
cal hypothyroidism in future later studies, to determine its rela-
tionship with other conditions and to determine whether patients
would benefit from early treatment, not only in the field of car-
diovascular risk, but other areas, such as the prevention of osteo-
porosis or possible mood disorders.
Given its association with lipid abnormalities, it would be intere-
sting to more accurately determine a possible association with the
likelihood of suffering a cardiovascular event and try to check over
the  long term if the starting of treatment decreases the inciden-
ce of such events  by comparison with a control population  and
if it does to establish it as prevention measure.
To treat or not to treat
At the end of the first decade of the third millennium, the contro-
versy continues over the need to treat mild hypothyroidism, known
as subclinical hypothyroidism (SCH). Those who treat with sub-
stitution therapy claim that it can deal with some symptoms that
may be due to thyroid failure, prevent the condition advancing to
overt hyperthyroidism and produce cardiovascular benefits.
Although theoretically treatment may prevent progression to overt
hypothyroidism, improve lipid profile (and hence cardiovascular
mortality) and improve symptoms, no studies of sufficient quality
to prove this exists.
Once the diagnosis is made an individual evaluation of the patient
must be made. A reasonable framework for action is the following:
Substitution treatment is indicated for: 
• Depression. Especially severe depression or depression
that resists treatment. 
• Pregnancy. Due to the adverse effects of hypothyroidism
on fetal neurodevelopment, survival of the fetus and its as-
sociation with toxemia and gestational hypertension.
• Children. So as not to interfere with their growth and de-
velopment.
• Hyperthyroidism with certain causes: auto-immune, post-I131,
post external radiotherapy, post partial thyroidectomy.
- TSH >10 mU/l.
• Goiter.
• Symptoms (fatigue or cognitive deficits) or dyslipidemia.
Perform test treatment for 3-6 months.
Doubts exist about the benefits of treatment in cases of: 
• Ischemic heart disease. For some authors, the doses used
are not contraindicated.
• Arrhythmias.
• Osteoporosis. 
• Patients over 60 years, especially those over 85 years, in
which subclinical hypothyroidism are associated with
longevity.
Some authors (31-34) have suggested that treatment with le-
vothyroxine may cause long-term osteoporosis, but there is no evi-
dence to support this theory, and studies have shown no difference
in bone density or fracture risk in patients undergoing treatment.
In our study we were able to see that there is a significant loss of
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bone mass a loss which increases with age, which leads us to re-
flect that it seems replacement therapy is necessary but it must
start when hypothyroidism is confirmed and once it has begun  both
the thyroid hormone and the loss of bone mass must be monito-
red, so treatment impede bone loss  can be begun if necessary.  
Therefore, the multiplicity and the possible improvement of sub-
clinical hypothyroidism associated with cardiovascular abnormalities
suggest that the decision to treat a patient should depend on the
presence of risk factors, rather than a threshold related to the de-
termination of TSH.
Furthermore, replacement therapy with levothyroxine may be su-
spended if there is no clear benefit and is generally safe as long
as excessive administration is avoided. This can be monitored by
serum levels of TSH.
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